Redsense Medical (REDS) investor relations material

Executive summary

• Net sales for Q2 2026 increased by 13% year-over-year to KSEK 7,090, with the US accounting for 99% of sales.

• Operating result (EBIT) turned positive at KSEK 377, compared to a loss of KSEK -1,833 in Q2 2025.

• Result after tax was KSEK 421, up from a loss of KSEK -1,830 in the prior year.

• Gross margin improved to 64% from 58% year-over-year.

• Cash on hand increased to KSEK 13,500 by August 14, 2026, following collection of a major receivable.

Financial highlights

• Net sales for H1 2026 reached KSEK 13,492, up from KSEK 11,052 year-over-year.

• Earnings per share for Q2 2026 were SEK 0.03, compared to SEK -0.11 in Q2 2025.

• Cash and cash equivalents at quarter-end were KSEK 4,615, rising to KSEK 13,500 post-period.

• Inventory increased to KSEK 12,045, supporting future demand.

• Solidity (equity/total assets) stood at 92%.

Outlook and guidance

• Focus remains on scaling growth in the US by increasing usage among existing providers and expanding to new clinics.

• Outside the US, efforts are on converting UK and German market progress into larger commercial opportunities for the Redsense Clamp.

• Continued financial and operational discipline is emphasized to support self-sustained growth.